Part
1
Part
2
Part
3
Part
4
参考文献
[1] WANG L J. Discussion of quality standard for pharmaceutical water and preparation in the system technology[J]. Chin J Pharm(中国医药工业杂志), 2018, 49(9): 1230-1238.
[2] 中国药典. 四部[S]. 2020: 〈0261〉制药用水.
[3] SANDLE T. Characterizing the microbiota of a pharmaceutical water system-A metadata study[J]. SOJ Microbiol Infect Dis, 2015, 3(2): 1-8.
[4] HU Y, HU D, YU X, et al. Evaluation for source water biosafety in Qiandao Lake, China[J]. Acta Sci Circumstantiae(环境科学学报), 2021, 41(2): 634-640.
[5] SHUKSHITH K S, GUPTA N V. Water for Pharmaceutical Use[J]. Int J Pharm Sci Rev Res, 2016, 36(1): 199-204.
[6] ZHANG W, BIAN C H, CHEN H, et al. Effect of microbiology ecology in main seal water system of power plants[J]. Nucl Power Eng(核动力工程), 2016, 37(S1): 64-67.
[7] ZHENG X L, WANG Y H, CAO W, et al. Establishment and analysis of microbial library in pharmaceutical water system of high-risk injection manufacturer[J]. Chin J Mod Appl Pharm(中国现代应用药学), 2021, 38(9): 1065-1068.
[8] LI M, ZHANG M, ZHONG Y W, et al. Spidemiological survey of an outbreak of nosocomial infection caused by Burkholderia cepacian[J]. Chin J Nosocomiol(中华医院感染学杂志), 2020, 30(15): 2326-2329.
[9] JIMENEZ L. Microbial diversity in pharmaceutical product recalls and environments[J]. PDA J Pharm Sci Technol, 2007,61(5): 383-399.
[10] SUTTON S, JIMENEZ L. A review of reported recalls involving microbiological control 2004-2011 with emphasis on FDA considerations of “Objectionable Organisms”[J]. Am Pharm Review, 2012, 15(1): 42-57.
[11] JIMENEZ L. Analysis of FDA enforcement reports(2012-2019) to determine the microbial diversity in contaminated non-sterile and sterile drugs[J]. Am Pharm Review, 2019, 22(6): 1-21.
[12] MOORE R A, TUANYOK A, WOODS D E. Survival of Burkholderia pseudomallei in water[J]. BMC Res Notes,2008(1): 11.
[13] LEWENZA S, ABBOUD J, POON K, et al. Pseudomonas aeruginosa displays a dormancy phenotype during long-term survival in water[J]. PLoS One, 2018, 13(9): e0198384.
[14] ZURITA J, MEJIA L, ZAPATA S, et al. Healthcare-associated respiratory tract infection and colonization in an intensive care unit caused by Burkholderia cepacia isolated in mouthwash[J].Int J Infect Dis, 2014(29): 96-99.
[15] JIMENEZ L, KULKO E, BARRON E, et al. Burkholderia cepacia: a problem that does not go away![J]. EC Microbiology, 2015, 2(1): 205-210
[16] RATAJCZAK M, KUBICKA M M, KAMIŃSKA D, et al.Microbiological quality of non-sterile pharmaceutical products[J]. Saudi Pharm J, 2015, 23(3): 303-307.
[17] VANEECHOUTTE M, KÄMPFER P, DE BAERE T, et al.Wautersia gen. nov., a novel genus accommodating the phylogenetic lineage including Ralstonia eutropha and related species, and proposal of Ralstonia[Pseudomonas] Syzygii(Roberts et al. 1990) comb. nov[J]. Int J Syst Evol Microbiol,2004, 54(Pt 2): 317-327.
[18] ADLEY C, SAIEB F. Microbials: Biofilm formation in high-purity water: Ralstonia pickettii a special case for analysis[J]. Ultrapure Water, 2005, 22(1): 14-19.
[19] MCBAIN A, ALLISON D, PLATTEN J, et al. Biofilms:Persistence and Ubiquity[M]. Cardiff: Biofilm Club, 2005.
[20] WANG X X, SONG Y Q, CAO Y D, et al. Pharmaceutical care for a patient with hemophilic lymphocytosis secondary to ralstonia bloodstream infection during pregnancy[J]. Central South Pharm(中南药学), 2021, 19(1): 130-133.
[21] WANG P L, WU Z P. Metagenomic next-generation sequencing for the diagnosis of Ralstonia pickettii meningitis:A case report and literature review[J]. J New Med(新医学),2020, 51(6): 478-481.
[22] YIN Y, LU F, XU J H, et al. Detection of blood contamination caused by Ralstonia pickettii during in vitro culture of Plasmodium falciparum[J]. J Pathog Biol(中国病原生物学杂志), 2018, 13(12): 1324-1326, 1334.
[23] RYAN M P, PEMBROKE J T, ADLEY C C. Ralstonia pickettii: A persistent gram-negative nosocomial infectious organism[J]. J Hosp Infect, 2006, 62(3): 278-284.
[24] ANDERSON R L, BLAND L A, FAVERO M S, et al. Factors associated with Pseudomonas pickettii intrinsic contamination of commercial respiratory therapy solutions marketed as sterile[J]. Appl Environ Microbiol, 1985, 50(6): 1343-1348.
[25] MCNEIL M M, SOLOMON S L, ANDERSON R L, et al.Nosocomial Pseudomonas pickettii colonization associated with a contaminated respiratory therapy solution in a special care nursery[J]. J Clin Microbiol, 1985, 22(6): 903-907.
[26] OIE S, KAMIYA A. Bacterial contamination of commercially available ethacridine lactate (acrinol) products[J]. J Hosp Infect, 1996, 34(1): 51-58.
[27] WANG S J, YU M, WANG G G, et al. Environment monitoring and environmental microbial library establishment in clean area of pharmaceutical industries[J]. Chin J Pharm(中国医药工业杂志), 2020, 51(10): 1334-1340.
撰稿人 | 李樱红、张林爽、李珏、郑小玲、王征南、王银环、陈君豪、洪亮、陶巧凤、陈欢
责任编辑 | 胡静
审核人 | 何发
2024-08-17
2024-09-02
2024-08-19
2024-08-15
2024-08-28
2024-09-04
2024-09-23
为提高生产效率、降低能源消耗,使药材受热均匀,有效成分更好地得到保留,本文对小柴胡颗粒连续逆流动态提取进行研究。以浸膏收率、黄芩苷鉴别、甘草鉴别、小柴胡鉴别、黄芩苷含量等为考察指标,采用 L9(34)正交试验优选小柴胡颗粒连续逆流动态提取工艺。结果显示优选的动态逆流提取连续生产工艺为:粗碎粒径 8mm、浸润时间 30min、加料转速 6rpm、饮用水流量 100L/h、提取转速 7rpm、提取时间 180min、提取温度 100℃,浸膏收率、黄芩苷鉴别、甘草鉴别、小柴胡鉴别、黄芩苷含量等均符合质量标准。因此,优选小柴胡颗粒连续逆流动态提取工艺重现性好,有效成分转移率高,为中药应用连续逆流动态提取提供了参考依据。
作者:石朝阳、姜许帆、张文标、乔晓芳
评论
加载更多